Thrombolysis in the treatment of peripheral arterial vascular occlusions

Arch Surg. 1987 Aug;122(8):901-5. doi: 10.1001/archsurg.1987.01400200051008.

Abstract

The efficacy of thrombolytic agents in the management of peripheral arterial disease remains unclear. We reviewed our experience with 64 consecutive episodes of limb-threatening graft or native vessel occlusions. The overall success rate was 59%, with a major complication/mortality rate of 28%. Thrombolytic therapy in patients with occluded vascular grafts required identification of a causative lesion and subsequent adjunctive management with percutaneous transluminal angioplasty or surgery for sustained patency (64%). In contrast, approximately 70% of native vessel occlusions maintained patency whether a causative lesion was identified and corrected or not. Patients who failed thrombolytic therapy had a worse prognosis overall, with 38% undergoing primary amputation, although patients with reconstructable occlusions still had a 64% salvage rate at six months. The review demonstrated that thrombolytic therapy continues to be a useful adjunct in treating the patient with peripheral vascular occlusion, although a significant risk of major complications persists. Patients with graft occlusions successfully treated with thrombolysis require correction of any precipitating lesions for long-term limb salvage, while careful management of patients failing thrombolysis can still achieve significant limb salvage in selected cases.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Angiography
  • Blood Vessel Prosthesis / adverse effects
  • Extremities / blood supply*
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Humans
  • Injections, Intra-Arterial
  • Ischemia / drug therapy*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Streptokinase / administration & dosage
  • Streptokinase / adverse effects
  • Thromboembolism / diagnostic imaging
  • Thromboembolism / drug therapy*
  • Urokinase-Type Plasminogen Activator / administration & dosage
  • Urokinase-Type Plasminogen Activator / adverse effects

Substances

  • Fibrinolytic Agents
  • Streptokinase
  • Urokinase-Type Plasminogen Activator